Keywords: اختلال دوپامین; Fenofibrate; Policosanol; Elderly; Mixed dyslipidemia;
مقالات ISI اختلال دوپامین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اختلال دوپامین; Dyslipidemia; Combined dyslipidemia; Mixed dyslipidemia; Atherogenic dyslipidemia; Child; Adolescent; Obesity
Keywords: اختلال دوپامین; Mixed dyslipidemia; Atherogenic index of plasma (AIPÂ =Â log[triglycerides/HDL-cholesterol]); Combined lipid-modifying therapy;
Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis
Keywords: اختلال دوپامین; ER niacin; Mixed dyslipidemia; Metabolic syndrome; Triglyceride; LDL; HDL; Inflammation; Insulin resistance; Interleukin-6; Apolipoprotein CIII;
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP
Keywords: اختلال دوپامین; Mixed dyslipidemia; Metabolic syndrome; Low-density lipoprotein; Very low-density lipoproteins; Remnants; High-density lipoprotein; CETP; Pitavastatin;
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia
Keywords: اختلال دوپامین; hyperlipidemia; mixed dyslipidemia; pitavastatin; pravastatin; remnant lipoprotein cholesterol;
Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial
Keywords: اختلال دوپامین; hyperlipidemia; LDL-C; mixed dyslipidemia; pitavastatin; pravastatin; risk factors;
Impaired fluidity and oxidizability of HDL hydrophobic core and amphipathic surface in dyslipidemic men
Keywords: اختلال دوپامین; AAPH; 2,2â²-azobis(2-methylpropionamidine) dihydrochloride; BMI; body mass index; CE; cholesteryl esters; CETP; cholesterol ester transfer protein; CRP; C-reactive protein, CVD, cardiovascular diseases; DTPA; diethylene triamine pentaacetic acid; HOMA-IR
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies
Keywords: اختلال دوپامین; Fenofibric acid; Rosuvastatin; Combination therapy; Mixed dyslipidemia; Lipoproteins;
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Keywords: اختلال دوپامین; Genetic variants; Combination therapy; Mixed dyslipidemia;
Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients
Keywords: اختلال دوپامین; simvastatin; mixed dyslipidemia; impaired glucose tolerance; lymphocytes; interleukin-2; interferon-γ;
Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose
Keywords: اختلال دوپامین; fenofibrate; mixed dyslipidemia; impaired fasting glucose; fibrinogen; factor VII; plasminogen activator inhibitor-I
Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances
Keywords: اختلال دوپامین; fenofibrate; Cytokines; Monocytes; mixed dyslipidemia; impaired fasting glucose; impaired glucose tolerance